Form 4: Silence Therapeutics Director Boosts Stake with Significant Share Purchases

Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc, has significantly increased his beneficial ownership through recent purchases of American Depositary Shares.

Summary

• Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc, acquired additional shares.
• On July 11, 2025, Mr. Griffiths directly acquired 28,000 American Depositary Shares (ADS) at a price of $6.43 per ADS, equivalent to 84,000 ordinary shares.
• Following this transaction, Mr. Griffiths' direct beneficial ownership stands at 11,715,365 ordinary shares.
• On July 15, 2025, an additional 43,293 American Depositary Shares (ADS) were acquired at a price of $6.40 per ADS, representing 129,879 ordinary shares, indirectly through Cream Capital Limited.
• Following this indirect acquisition, the total beneficial ownership (direct and indirect) is 11,758,658 ordinary shares.
• Mr. Griffiths is a director and controlling shareholder of Cream Capital Limited and disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest.

Sentiment

Score: 8

Explanation: The significant purchases by a director and 10% owner indicate strong insider confidence in the company's prospects, which is generally a very positive signal for investors.

Positives

• A Director and 10% owner, Richard Ian Griffiths, has increased his stake in Silence Therapeutics plc, signaling confidence in the company's future prospects.
• The purchases were made at prices of $6.43 and $6.40 per American Depositary Share, indicating a specific valuation at which the insider found the shares attractive.
• The total acquisition of 71,293 American Depositary Shares (equivalent to 213,879 ordinary shares) represents a substantial investment by a key insider.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This Form 4 filing details an insider transaction for Silence Therapeutics plc, a company likely in the biotechnology or pharmaceutical sector given its name. Insider buying can be a positive signal within the industry, suggesting that those with intimate knowledge of the company's operations and pipeline believe in its future value, potentially indicating positive developments not yet fully public or a belief that the stock is undervalued.

Comparison to Industry Standards

• This document is a standard SEC Form 4 filing, reporting insider transactions. There are no specific company or project results to compare against global benchmarks.
• The transaction itself, an insider purchase, is a common occurrence across all industries. For example, similar insider purchases have been reported by executives at biotech firms like Moderna (MRNA) or Pfizer (PFE) when they believe in their company's pipeline or market position.
• The size of the purchase (over $450,000 based on the ADS prices) is significant for an individual insider, comparable to substantial investments seen from directors in other mid-cap biotech companies.

Related Party Transactions

• The indirect acquisition of 43,293 American Depositary Shares was made through Cream Capital Limited, where Mr. Griffiths is a director and the controlling shareholder. This constitutes a related party transaction. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

Stakeholder Impact

• Shareholders: The insider buying by a significant shareholder and director could instill greater confidence in the company's stock, potentially leading to increased investor interest and a positive impact on share price.

Key Dates

Recommendation

Keywords

Silence Therapeutics plc, SLN, Form 4, Insider Trading, Share Purchase, Director, Beneficial Ownership, American Depositary Shares, Equity Acquisition, Richard Ian Griffiths, Cream Capital Limited